Vladonix

Short peptide complex penetrates cell nuclei and modulates gene expression in thymic and T-lymphocyte cells. Promotes T-cell maturation, normalizes CD4/CD8 ratios, and supports cytokine balance.

Vladonix is a Khavinson-class peptide bioregulator derived from thymus tissue, developed as part of Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore immune function in aging subjects by modulating gene expression in thymic epithelial cells and thymus-dependent lymphocyte populations. As a thymic tissue-derived bioregulator, Vladonix shares its mechanistic framework with thymalin, the better-characterized Khavinson thymus compound; both are proposed to interact with chromatin regulatory elements in thymic cells to reactivate gene expression programs that decline with immunosenescence, potentially restoring T-cell maturation and peripheral immune competence. Published research from the Khavinson group on thymus-derived short peptides, including thymalin, has demonstrated human hematopoietic stem cell differentiation activity, immune modulation in aged subjects, and class-level evidence for thymic peptide bioregulation, providing biological plausibility for this compound class. Vladonix has no FDA approval and no approved indication in any Western jurisdiction; it is the commercial thymic bioregulator product distinct from thymalin but sharing the same class evidence framework, with no independent published clinical trials specific to this formulation, and its use is confined to the Russian integrative and anti-aging medicine context.